clinical trial · NCT07396584
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Hutchmed·phase2·recruiting·n = 186
Solid Tumors, AdultHMPL-A580HMPL-A580
brief summary
This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.
started
Mar 4, 2026
primary completion
Dec 31, 2028
completion
Jan 30, 2029
last updated
Mar 27, 2026
detailed description
To evaluate the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A580 in solid tumors.
To characterize the safety, tolerability, and preliminary efficacy of HMPL-A580 at RDE(s) to determine recommended dose(s) for phase 2 dose (RP2D) or phase 3 dose (RP3D) in participants with selected solid tumors.
official title
A Phase I/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol